Information message

In order to see all the search results and access content, you must log in. Please use the Log-in button at the top of the page.

Displaying 85 - 96 of 435

EASL Policy Dialogues S2 E7: Inequality in liver care – Identifying and addressing disparities

Description

This episode focuses on liver cancer disparities in Europe. Liver cancer incidence disproportionately affects marginalized groups and deaths from liver cancer have continued to increase over the last decades. This episode addresses gaps in care, causes for inequities, and actions being taken at the EU level to improve liver cancer prevention.

The EASL Policy Dialogues are supported by CymaBay, Echosens, Grifols and Novo Nordisk. CymaBay, Echosens, Grifols and Novo Nordisk have had no input into the content of the EASL Policy Dialogues.

 

Speakers

  
Josep Llovet

Josep M. Llovet, MD, PhD is Professor of Medicine – Hepatic Oncology at University of Barcelona, Group leader and Professor of Research-ICREA in the Liver Unit, IDIBAPS-Hospital Clinic and Director of the Liver Cancer Program and Professor of Medicine at the Icahn School of Medicine at Mount Sinai, NY. He has devoted his career to the pathogenesis and treatment of liver cancer, publishing ~ 350 articles (~ 136,049 citations, h index: 134) and leading ~100 projects. He has been nominated as global Top-1% cited researcher (2014 to 2022) and nominated Editor in Chief of JHEP Reports (2024-29).
Richard Price

Richard Price is Head of Policy at European Cancer Organisation (ECO). He is a public policy professional with extensive experience in the healthcare and pharmaceutical sectors working as a policy manager in EU Affairs at ECO, policy and advocacy officer at the European Association of Hospital Pharmacists, and as policy advisor to the Pharmaceutical Society of Northern Ireland.

Log in to post comments

EASL Policy Dialogues S2 E8: The political battle to reduce harms caused by alcohol

Description

The Awareness Week on Alcohol Related Harm (AWARH) serves to raise awareness for the incredibly high levels of alcohol consumption in Europe. AWARH week is designed to showcase policies that can be implemented at the EU and national levels to reduce population-level alcohol consumption. In this episode, Professor Nick Sheron, a clinical hepatologist, and Florence Berteletti, a public policy professional come together to discuss challenges in implementing alcohol policies and current initiatives taking place in Europe to address those obstacles.

The EASL Policy Dialogues are supported by CymaBay, Echosens, Grifols and Novo Nordisk. CymaBay, Echosens, Grifols and Novo Nordisk have had no input into the content of the EASL Policy Dialogues.

 

Speakers

  
Nick Sheron

Nick Sheron is an academic clinical hepatologist at University of Southampton and runs the liver unit at Southampton General Hospital. He is also actively involved in a clinically based programme of research in various aspects of alcohol-related problems. Together with Ian Gilmore, President of the Royal College of Physicians, he co-founded the Alcohol Health Alliance UK, an umbrella body bring together 27 different organisations including Royal Colleges, NGOs and charities with the aim of lobbying for evidence-based policies to reduce alcohol-related harm in the UK. He is also a founder member of the European Union Alcohol Forum, a member of the European Union Alcohol Marketing Taskforce and two bodies of which have been set up by the European Commission in order to take forward the EU Alcohol Strategy.

Florence Berteletti

Florence Berteletti has over 20 years of international policy and advocacy experience in diverse fields including fiscal policies for health, tobacco control, alcohol related harm and culture policy. Florence Berteletti was appointed Secretary General of Eurocare in August 2021. Between 2018 and August 2021, Florence was Advocacy Director at the World Heart Federation where she was responsible for leading WHF’s global policy and advocacy and led dossiers related to Front of Pack Labelling, Fiscal Policies for Health, Rheumatic Heart Diseases and Air pollution, to name just a few. Before WHF, Florence was Director of the Smoke Free Partnership (SFP), an alliance of 52 civil society organisations dedicated to the implementation of the WH Framework Convention on Tobacco Control (FCTC).
Log in to post comments

EASL Studio S5 E13: Basics in decision-making for liver cancer treatment

Description

With cases of hepatocellular carcinoma on the rise and representing the end stage of many chronic liver diseases, the treatment of liver cancer has become one of the most dynamic areas in hepatology. The focus of this episode is on answering practical clinical questions, examining trial data, and sharing clinical insights that may be useful for decision-making in daily clinical practice.

Faculty

  • Tom Lüdde (Moderator)
  • Christoph Roderburg (Faculty)
  • Anna Saborowski (Faculty)
  • Arndt Vogel (Faculty)

This EASL Studio is supported by AstraZeneca and Eisai. EASL has received no input from AstraZeneca or Eisai with regards to the content of this programme.

Related episodes

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments
Liver Tumours
EASL Studio Podcast S5 E13: Basics in decision-making for liver cancer treatment

EASL Studio Podcast S5 E13: Basics in decision-making for liver cancer treatment

Podcasts
View

EASL Studio S5 E12: PSC and AIH overlap syndrome: does it actually exist?

Description

This episode explores key aspects of intriguing intersection of autoimmune liver diseases, such as their distinctive presentations in childhood and adulthood and the influence of inflammatory bowel disease on liver disease phenotypes. The speakers also examines the benefits and risks associated with immunosuppressive treatments in managing these complex conditions.

Faculty

  • Palak Trivedi (Moderator)
  • Amanda Ricciuto (Faculty)
  • Marianne Samyn (Faculty)
  • Christoph Schramm (Faculty)

This EASL Studio is supported by Chemomab Therapeutics. EASL has received no input from Chemomab Therapeutics with regards to the content of this programme.

Related episodes

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments
Immune-Mediated and Cholestatic Diseases
EASL Studio Podcast S5 E12: PSC and AIH overlap syndrome: does it actually exist?

EASL Studio Podcast S5 E12: PSC and AIH overlap syndrome: does it actually exist?

Podcasts
View

EASL Studio S5 E11: Statins in cirrhosis: The window hypothesis again, or just a closed window?

Description

The treatment of liver cirrhosis – currently based on symptomatic management of complications – has barely changed in last 20 years. In this episode, the experts discuss the use of statins, for which there is growing body of evidence of their beneficial effects in patients suffering with cirrhosis.

Faculty

  • Thomas Reiberger (Moderator)
  • Juan Gonzalez-Abraldes (Faculty)
  • Elisa Pose (Faculty)
  • Jonel Trebicka (Faculty)

This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.

Related episodes

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments
Immune-Mediated and Cholestatic Diseases
Quiz: Which of the following constitute a good phenotypic prognostic factor in patients with primary sclerosing cholangitis?

Quiz: Which of the following constitute a good phenotypic prognostic factor in patients with primary sclerosing cholangitis?

Quiz
View
Cirrhosis & Complications
EASL Studio Podcast S5 E11: The window hypothesis again, or just a closed window?

EASL Studio Podcast S5 E11: The window hypothesis again, or just a closed window?

Podcasts
View

EASL Studio S5 E7: Why bother with diet and exercise when an injection will suffice?

Description

During this episode, the experts discuss of what it really takes to implement a successful lifestyle modification in behavioural therapy. Tune in to learn tools and tips that can help treat patients in improving their liver health and quality of life.

This episode was scheduled according to the international calendar for the World Food Day (16 October)

    Faculty

    • Shira Zelber Sagi (Moderator)
    • Riccardo Dalle Grave (Faculty)
    • Giulio Marchesini (Faculty)

    Related episodes

    ℹ️ Please click here to access the podcast version of this EASL Studio episode.

    Log in to post comments

    EASL Studio S5 E10: Why should diabetologists care about the liver?

    Description

    In this episode, participants tackle the relationship between metabolic dysfunction-associated steatotic liver diseases (MASLD) and type 2 diabetes (T2D), exploring their prevalence and the potential for more aggressive outcomes. Experts weigh in on the pressing questions of whether non-invasive test thresholds should be adapted for MASLD patients with T2D and which drugs should take precedence as first-line treatments for high-risk MASLD cases.

    Faculty

    • Zobair Younossi (Moderator)
    • Laurent Castera (Faculty)
    • Camilla Dalby Hansen (Faculty)
    • Amalia Gastaldelli (Faculty)

    This episode is scheduled according to the international calendar for the World Diabetes Day (14 November).

    This EASL Studio is supported by Boehringer Ingelheim and Novo Nordisk. EASL has received no input from Boehringer Ingelheim or Novo Nordisk with regards to the content of this programme.

    Related episodes:

    ℹ️ Please click here to access the podcast version of this EASL Studio episode.

    Log in to post comments
    Metabolism, Alcohol & Toxicity
    EASL Studio Podcast S5 E10: Why should diabetologists care about the liver?

    EASL Studio Podcast S5 E10: Why should diabetologists care about the liver?

    Podcasts
    View
    Displaying 85 - 96 of 435